Attovia Therapeutics Inc. (ATTO)
NYSE
20.62
-0.18 (-0.87%)
Closed
Aug 24, 2026
Day's Range
19.7420.96
52 wk Range
16.1524.32
Financial Statements - ATTO - Attovia Therapeutics Inc.
Revenue
1.35M
Net Income
-60.62M▼ 52.3%Net Margin -4490.9%
EBITDA
-66.35M▼ 60.9%
Free Cash Flow
-61.51M▼ 67.1%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Sales | 1.35M | 0 | 1.44B | 1.41B | 1.70B |
| Cost of Goods | - | - | 93.80M | 72.30M | 66.40M |
| Gross Profit | - | - | 1.35B | 1.34B | 1.64B |
 Operating Expense | - | - | - | - | - |
| Operating Income | -67.15M | -41.55M | 16.40M | 40.30M | 33.10M |
| Non-Operating Interest | - | - | - | - | - |
| Other Income Expense | -95K | -1.68M | -64.90M | -27.70M | -29.50M |
| Pre Tax Income | -60.62M | -39.80M | -84.40M | -41.70M | -44.50M |
| Income Tax | - | - | 5.80M | 5.10M | 36.20M |
| Net Income | -60.62M | -39.80M | -90.30M | -46.80M | -80.70M |
| EPS Basic | -2.37 | -1.754732 | -6.61 | -3.33 | -5.63 |
| EPS Diluted | -2.37 | -1.754732 | -6.61 | -3.33 | -5.63 |
| Basic Shares Outstanding | 25.46M | 25.67M | 14.06M | 14.08M | 14.44M |
| Diluted Shares Outstanding | 25.46M | 25.67M | 14.06M | 14.08M | 14.44M |
| Ebit | -67.15M | -41.55M | 7.50M | 28.20M | 23.60M |
| Ebitda | -66.35M | -41.24M | 205.70M | 176.90M | 204.40M |
| Net Income Continuous Operations | -60.62M | -39.80M | -84.50M | -41.70M | -44.50M |
| Minority Interests | - | - | 0 | 0 | -600K |
| Preferred Stock Dividends | 271K | 5.24M | -1K | - | - |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
